Detecting cancer early with advanced flow cytometry
bioAffinity Technologies addresses the urgent need for noninvasive, early-stage cancer diagnosis and targeted cancer treatment. Our first product, CyPath® Lung, accurately diagnoses early-stage lung cancer, the leading cause of cancer-related deaths.
Diagnostics
CyPath® Lung is a non-invasive, cost-effective, and accurate test to detect early-stage lung cancer in patients at high risk.
Therapeutics
Through our subsidiary, OncoSelect® Therapeutics, we are advancing our discoveries to create broad-spectrum cancer therapeutics.
Early Detection of Cancer and Targeted Treatment Saves Lives
CyPath® Lung Flow Cytometry Test for Lung Cancer
Addressing a critical need to find cancer early and treat cancer specifically bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. Our first product, CyPath® Lung Flow Cytometry Test for Lung Cancer (CyPath® Lung), has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test.
Specificity ⃰
⃰ In individuals at high risk for lung cancer with nodules less than 20 mm, (n=132)
Precision Pathology Services
Learn More about CyPath® Lung
The CyPath® Lung Flow Cytometry Test has been licensed by Precision Pathology Services for commercial sale as a Laboratory Developed Test (LDT).
CyPath® Lung is a non-invasive test that assists clinical decision-making in lung cancer patients whose low-dose computed tomography (LDCT) has demonstrated a suspicious finding.
The test reveals the lung micro-environment by automated analysis of sputum using flow cytometry to characterize cell populations indicative of cancer in the lung.
Physician Portal
Patient Portal
How to Order
CyPath® FAQ
Early Detection of Lung Cancer Saves Lives
Meeting a Critical Need to Detect Lung Cancer Early
Addressing a critical need to find cancer early and treat cancer specifically bioAffinity Technologies develops tests and therapies to detect and treat cancer at the cellular level. Our first product, CyPath® Lung Flow Cytometry Test for Lung Cancer (CyPath® Lung), has been licensed by Precision Pathology Services for continued development and commercial sale as a Laboratory Developed Test.
At-Home Sample Collection
With the at-home sample collection kit, a person can cough up a sputum sample with the help of a simple, non-invasive assist device that acts to break up mucus in the lung.
Flow Cytometry
Automated Data Analysis
Automated data analysis is built into the process that identifies cancer in the lung, with results in minutes. Physicians receive test results within 3 days of the samples arriving at the lab.
CyPath® Lung is ordered by physicians for patients who they suspect have lung cancer. CyPath® Lung has the potential to dramatically increase overall diagnostic accuracy leading to increased survival, fewer unnecessary invasive procedures, and lower patient anxiety and medical costs.
Research & Development Efforts
Scientific Publications & Abstracts
bioAffinity’s Diagnostics Efforts
CyPath® uses a porphyrin molecule that displays an unusually high affinity to bind to cancer cells that fluoresce brightly when labeled to distinguish cancer from non-cancer cells using flow cytometry.
Our innovative scientific research is aimed at developing non-invasive diagnostics for various cancers and other lung diseases. Our first test, CyPath® Lung, is available through Precision Pathology Services to physicians for their patients at high risk for lung cancer.
This animated video produced by the Massachusetts Institute of Technology (MIT) Star CellBio introduces flow cytometry, a technique in which cells are suspended in a fluid and flow one at a time through a focus of exciting light, which is scattered in patterns characteristic to the cells and their components.
bioAffinity’s Therapeutics Efforts
Through our subsidiary, OncoSelect® Therapeutics, our company focuses on advancing discoveries related to broad-spectrum cancer therapeutics. In researching porphyrins’ selectivity for cancer, we discovered novel therapies that kill cancer cells without harm to normal cells in vitro.
We will continue with animal studies to advance our discoveries. Our research also looks to attach cancer-killing cytotoxic drugs to porphyrins, a cancer-selective molecule that is taken up by tumors in much greater amounts than by non-cancer tissue.
Animation of a Porphyrin molecule
bioAffinity’s Therapeutics Efforts
Through our subsidiary, OncoSelect® Therapeutics, our company focuses on advancing discoveries related to broad-spectrum cancer therapeutics. In researching porphyrins’ selectivity for cancer, we discovered novel therapies that kill cancer cells without harm to normal cells in vitro.
We will continue with animal studies to advance our discoveries. Our research also looks to attach cancer-killing cytotoxic drugs to porphyrins, a cancer-selective molecule that is taken up by tumors in much greater amounts than by non-cancer tissue.
Animation of a Porphyrin molecule